The Registry of Genetic Expression of Taiwan Urologic Cancer

This project is a nationwide precision medicine program for urothelial carcinoma and renal cell carcinoma.

Inclusion Criteria:Ages 20 and above. (Age >= 18 years old from January 1, 2023).Pathological reports showed renal cell carinoma or urothelial carcinoma.muscle-invasive bladder cancer or positive of N/M grade, UTUC of T2 at least or positive of N/M grade, or stage III/IV RCCWillingness to provide the residual biopsy/operative tumor samples for study.Life expectancy more than 3 months.Patients fully understand the protocol with the willingness to have regular follow-up.Exclusion Criteria:Inability to cooperate by providing a complete medical history.Ineligible tumor tissue samples for next-generation sequencing of genetic testing.Undesirable compliance.Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.